8-K current report · filed Aug 6, 2026

Corvus Pharmaceuticals, Inc. (CRVS) 8-K Current Report: August 6, 2026

Item 2.02Item EX-99.1CRVS overview

Short answer

Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Corvus Pharmaceuticals’ financial results for the three and six months ended June 30, 2026.

Corvus Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Corvus Pharmaceuticals’ financial results for the three and six months ended June 30, 2026
  • Financial position as of June 30, 2026 and a business update announced August 6, 2026
  • Detailed results and operating developments available in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 net loss $18.0M, or $0.19 per share, versus $8.0M loss, reflecting sharply higher development spending
  • Research and development expense $16.0M, up from $7.9M, as enrollment advances across Phase 3 PTCL and Phase 2 atopic dermatitis trials
  • Cash, equivalents and marketable securities $215.2M, including $189.4M financing proceeds, supporting operations into 2Q28
  • Soquelitinib Phase 3 PTCL trial targets 150 patients, with progression-free survival as the primary endpoint
  • Corvus invested $5.0M in Angel Pharma’s $13.5M financing, supporting atopic dermatitis and planned asthma development in China

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Corvus Pharmaceuticals, Inc. 8-K filings

Get the next CRVS 8-K as it lands

Follow CRVS for push alerts, or ask the research agent what this filing means.